Xeris Biopharma Holdings, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $291.8M | $203.1M | $163.9M | $110.2M | $49.6M |
| Selling, general & administrative | $182.4M | $163.5M | $146.1M | $137.7M | $125.7M |
| Research and development | $31.2M | $25.6M | $22.3M | $21.0M | $25.2M |
| Operating income | $24.9M | -$33.6M | -$44.0M | -$81.9M | -$115.2M |
| Interest expense | $29.1M | $30.5M | $26.6M | $14.1M | $7.2M |
| Pretax income | $554,000 | -$57.1M | -$63.5M | -$96.1M | -$122.7M |
| Income tax expense | $0 | -$2.3M | -$1.2M | -$1.4M | $0 |
| Net income | $554,000 | -$54.8M | -$62.3M | -$94.7M | -$122.7M |
| Balance Sheet | |||||
| Cash and equivalents | $111.0M | $71.6M | $67.4M | $122.0M | $67.3M |
| Current assets | $240.3M | $167.7M | $156.3M | $186.8M | $142.6M |
| Total assets | $383.5M | $323.1M | $322.6M | $344.5M | $304.4M |
| Current liabilities | $109.6M | $100.4M | $95.2M | $73.6M | $79.0M |
| Total liabilities | $369.8M | $352.7M | $329.4M | $299.3M | $209.1M |
| Total debt | $233.6M | $248.8M | $198.8M | $197.2M | — |
| Stockholders' equity | $13.7M | -$29.6M | -$6.8M | $45.2M | $95.2M |
| Cash Flow Statement | |||||
| Cash from operations | $28.6M | -$37.0M | -$47.0M | -$102.9M | -$95.5M |
| Depreciation and amortization | $1.3M | $1.2M | $1.5M | $1.4M | $1.3M |
| Stock-based compensation | $22.4M | $18.4M | $10.7M | $12.2M | $11.4M |
| Capital expenditure | — | — | — | — | $1.1M |
| Free cash flow | — | — | — | — | -$96.6M |
| Impairments | $0 | $0 | $0 | $0 | — |
Shares outstanding 172.6M · Free float 92.2%
Annual filing data through FY ended December 31, 2025; float as of July 16, 2026.